A variety of developmental changes is of influence on the pharmacokinetics and
pharmacodynamics of midazolam in neonatal and pediatric intensive care patients …

Objective To describe the pharmacokinetics of midazolam, a water‐soluble benzodiazepine
with a short half‐life, in critically ill neonates. Hypothesis Midazolam clearance is reduced in …

Although midazolam is a frequently used sedative in neonatal intensive care units, its use in
preterm neonates has been off‐label. Recently, a new dosing advice for midazolam for …

Objective: To determine the minimal effective dose (MED) of intravenous midazolam,
required for appropriate sedation in 95% of patients, 1 h after drug administration. Methods …

Objective: To evaluate the effects of intravenous midazolam on haemodynamic variables
and cerebral blood flow velocity (CBFV) and to determine the pharmacokinetics using a …

OBJECTIVE: To determine the steady-state plasma concentrations of midazolam in critically
ill infants and children. DESIGN: Prospective uncontrolled study conducted over 18 months …

The interest in midazolam as a sedative for pediatric patients has continued to increase.
Clinical and pharmacokinetic studies are further refining doses and routes of administration …

Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug‐
metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to …

Objective: To determine efficacy of midazolam as a sedative in mechanically ventilated
newborns. Design: Double blind randomized placebo controlled trial. Setting: Neonatal Unit …

Midazolam is a water soluble benzodiazepine, with a short elimination half-life in adults and
children. An IV bolus of midazolam 0.2 mg· kg− 1 was administered to 10 critically ill …